Artificial intelligence applied to clinical trials: opportunities and challenges
S Askin, D Burkhalter, G Calado, S El Dakrouni - Health and technology, 2023 - Springer
Abstract Background Clinical Trials (CTs) remain the foundation of safe and effective drug
development. Given the evolving data-driven and personalized medicine approach in …
development. Given the evolving data-driven and personalized medicine approach in …
[HTML][HTML] Artificial intelligence in pancreatic cancer
B Huang, H Huang, S Zhang, D Zhang, Q Shi, J Liu… - Theranostics, 2022 - ncbi.nlm.nih.gov
Pancreatic cancer is the deadliest disease, with a five-year overall survival rate of just 11%.
The pancreatic cancer patients diagnosed with early screening have a median overall …
The pancreatic cancer patients diagnosed with early screening have a median overall …
Are deep learning structural models sufficiently accurate for virtual screening? application of docking algorithms to AlphaFold2 predicted structures
AM Díaz-Rovira, H Martín, T Beuming… - Journal of Chemical …, 2023 - ACS Publications
Machine learning-based protein structure prediction algorithms, such as RosettaFold and
AlphaFold2, have greatly impacted the structural biology field, arousing a fair amount of …
AlphaFold2, have greatly impacted the structural biology field, arousing a fair amount of …
[HTML][HTML] The Role of Artificial Intelligence on Tumor Boards: Perspectives from Surgeons, Medical Oncologists and Radiation Oncologists
V Nardone, F Marmorino, MM Germani… - Current …, 2024 - mdpi.com
The integration of multidisciplinary tumor boards (MTBs) is fundamental in delivering state-of-
the-art cancer treatment, facilitating collaborative diagnosis and management by a diverse …
the-art cancer treatment, facilitating collaborative diagnosis and management by a diverse …
[HTML][HTML] Modeling the efficacy of different anti-angiogenic drugs on treatment of solid tumors using 3D computational modeling and machine learning
Accurate simulation of tumor growth during chemotherapy has significant potential to
alleviate the risk of unknown side effects and optimize clinical trials. In this study, a 3D …
alleviate the risk of unknown side effects and optimize clinical trials. In this study, a 3D …
A systematic literature review for the prediction of anticancer drug response using various machine‐learning and deep‐learning techniques
Computational methods have gained prominence in healthcare research. The accessibility
of healthcare data has greatly incited academicians and researchers to develop executions …
of healthcare data has greatly incited academicians and researchers to develop executions …
TDC-2: Multimodal Foundation for Therapeutic Science
Abstract Therapeutics Data Commons (tdcommons. ai) is an open science initiative with
unified datasets, AI models, and benchmarks to support research across therapeutic …
unified datasets, AI models, and benchmarks to support research across therapeutic …
Machine learning algorithms and biomarkers identification for pancreatic cancer diagnosis using multi-omics data integration
AK Rouzbahani, G Khalili-Tanha, Y Rajabloo… - … -Research and Practice, 2024 - Elsevier
Purpose Pancreatic cancer is a lethal type of cancer with most of the cases being diagnosed
in an advanced stage and poor prognosis. Developing new diagnostic and prognostic …
in an advanced stage and poor prognosis. Developing new diagnostic and prognostic …
Predicting Phase 1 Lymphoma Clinical Trial Durations Using Machine Learning: An In-Depth Analysis and Broad Application Insights
B Long, SW Lai, J Wu, S Bellur - Clinics and Practice, 2023 - mdpi.com
Lymphoma diagnoses in the US are substantial, with an estimated 89,380 new cases in
2023, necessitating innovative treatment approaches. Phase 1 clinical trials play a pivotal …
2023, necessitating innovative treatment approaches. Phase 1 clinical trials play a pivotal …
Correlation Between Early Trends of a Prognostic Biomarker and Overall Survival in Non–Small-Cell Lung Cancer Clinical Trials
H Loureiro, TM Kolben, A Kiermaier… - JCO Clinical Cancer …, 2023 - ascopubs.org
PURPOSE Overall survival (OS) is the primary end point in phase III oncology trials. Given
low success rates, surrogate end points, such as progression-free survival or objective …
low success rates, surrogate end points, such as progression-free survival or objective …